Regeneron Pharmaceuticals Conference Call Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date**: March 11, 2026 - **Key Speakers**: Marion McCourt (Executive Vice President of Commercial), Ryan Crowe (Senior Vice President of Investor Relations and Strategy) Core Industry Insights Commercial Performance - **EYLEA HD**: - Q4 sales reached **$506 million**, marking a **66% year-over-year growth** [11] - Label enhancements in November included weekly dosing and RVO indication [11] - **DUPIXENT**: - Q4 sales totaled **$4.9 billion**, a **32% increase** year-over-year [12] - Strong performance across all indications, with significant growth in asthma and new launches in COPD and CSU [13][14] - **Libtayo**: - Generated **$525 million** in Q4, a **13% year-over-year increase** [12] Market Dynamics - **DUPIXENT** remains the leading product in its category, with significant under-penetration in atopic dermatitis [13] - EYLEA is facing competition from biosimilars, leading to expected declines in its sales, although EYLEA HD is showing high single-digit growth [16][17] - The company anticipates additional biosimilar competition for EYLEA in the second half of the year [17] Pipeline Developments New Product Launches - **Lynozyfic**: Recently launched for later-line patients, showing positive uptake [14] - **Cemdisiran**: Expected approval for generalized myasthenia gravis (MG) by early next year, with a potential market size of **$5 billion** today, projected to reach **$10 billion** by 2030 [47] - **Geographic Atrophy (GA)**: Combination therapy with cemdisiran and pozelimab is in development, with interim analysis expected by the end of 2026 [55] Strategic Partnerships - The alliance with **Sanofi** has been crucial for the success of DUPIXENT, with **1.4 million patients** currently on the medication [26] - Discussions are ongoing regarding the potential extension of the alliance and leveraging both companies' pipelines for future growth [27][28] Financial Strategy - Regeneron emphasizes a disciplined approach to capital allocation and is open to M&A opportunities that align with its therapeutic focus [21][22] - The company is building out its commercial infrastructure to support new product launches and expand its therapeutic areas [22][40] Risks and Considerations - The company acknowledges the risks associated with forward-looking statements and the potential impact of biosimilar competition on EYLEA sales [3][4] - There is a focus on ensuring the safety and efficacy of new products in the market, particularly in the context of competitive pressures [36] Conclusion - Regeneron Pharmaceuticals is positioned for continued growth with a strong commercial performance in key products like DUPIXENT and EYLEA HD, while also expanding its pipeline with promising new therapies. The strategic alliance with Sanofi remains a cornerstone of its success, and the company is actively exploring opportunities for future growth through M&A and new product launches.

Summary of Regenxbio FY Conference Call (March 10, 2026) Company Overview - **Company**: Regenxbio (NasdaqGS: RGNX) - **Key Products**: DUPIXENT, EYLEA, linvoseltamab, fianlimab, LIBTAYO Core Industry Insights DUPIXENT - **Sales Performance**: Achieved $17.8 billion in sales for the previous year, representing a 32% year-over-year growth [8][9] - **Market Position**: Positioned well with growth anticipated across all 9 FDA-approved indications, including recent launches for chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) [3][9] - **Launch Success**: Strong start for CSU and significant unmet need addressed by COPD, with robust payer coverage and enthusiasm from pulmonologists [10][11] - **Life Cycle Management**: Plans for new long-acting formulations (Super Dupie) and other antibodies targeting IL-4 and IL-13 to sustain revenue against emerging competition [19][20][21] EYLEA - **Sales Growth**: Reported $506 million in sales for EYLEA HD, up 66% year-over-year [22] - **Product Enhancements**: Anticipation of prefilled syringe approval expected to enhance operational workflows in retinal clinics [22][23] - **Market Dynamics**: Expectation of double-digit sequential decline in EYLEA sales due to biosimilar competition, while transitioning patients to EYLEA HD [25][26] Linvoseltamab - **Market Opportunity**: Targeting a refractory patient population in fourth-line myeloma, with potential expansion into earlier lines of therapy [34][35] - **Patient Population**: Approximately 3,000-4,000 patients in the U.S. for the fourth-line setting, with aspirations to capture a larger share of the $30 billion market [35][36] Obesity Program - **Product Development**: Olatorepatide shows promising results with 19% weight loss in pivotal data from China, with plans for U.S. phase 3 studies [27][28] - **Combination Therapy**: Exploring co-formulation of alirocumab (Praluent) with olatorepatide to address dual needs of weight loss and LDL cholesterol reduction [29][30] Key Catalysts and Future Outlook - **Pipeline Readouts**: Anticipated interim readouts for geographic atrophy and PNH towards the end of the year, with pivotal data from Factor XI expected in the first half of next year [39][40] - **Competitive Landscape**: Monitoring competitor readouts for insights and potential impacts on Regenxbio's strategies [40] Additional Insights - **Regulatory Risks**: Forward-looking statements are subject to risks and uncertainties, with no obligation to update based on new information [5] - **Market Education**: Emerging competition in atopic dermatitis is seen as beneficial for DUPIXENT by increasing market education and awareness [17][18] This summary encapsulates the key points discussed during the conference call, highlighting Regenxbio's strategic positioning, product performance, and future opportunities within the biopharmaceutical industry.

Regeneron Pharmaceuticals FY Conference Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Event**: FY Conference held on March 04, 2026 Key Industry Insights - **Clinical Programs**: Regeneron is actively working on **50 clinical programs**, which are not fully reflected in the current valuation of the company [2][4] - **Earnings Growth**: Projected earnings could reach **$70 to $80** per share in the next two to three years, potentially leading to a share price exceeding **$1,000** if trading at historical multiples [4][5] Core Business Drivers - **EYLEA HD**: Transitioning from EYLEA 2 mg to EYLEA HD, with recent approvals for every-four-week dosing and RVO, which represents **20%** of the market opportunity [6][7] - **DUPIXENT**: Annualized revenue for DUPIXENT was just under **$5 billion** in Q4, with expectations for continued growth due to recent launches and expansions [7][8] - **Development Balance Repayment**: Expected repayment of approximately **$600 million** by mid-2026, leading to benefits in the second half of the year and beyond [8][9] Pipeline Developments - **Oncology Franchise**: Libtayo is expected to perform well following its launch in adjuvant CSCC, with a sizable market opportunity of **20,000 patients** in the U.S. and abroad [32] - **Cemdisiran**: Targeting myasthenia gravis with a potential launch in **2026**, and pivotal studies for PNH expected to read out by **2027** [36][37] - **Long-acting Products**: Development of long-acting IL-13 and IL-4 blockers, with plans to enter clinical trials soon [24][25] Financial Management - **R&D Investment**: Projected **$6 billion** in R&D expenses for 2026, focusing on late-stage programs [10] - **Tax Rate**: Expected to remain in the mid-teens range, influenced by stock-based compensation [11] - **Cash Reserves**: Approximately **$19 billion** in cash, with plans for strategic investments and share repurchases [50][52] Intellectual Property and Lifecycle Management - **DUPIXENT IP**: Composition of matter patent expires in **2031** in the U.S., with additional patents extending into the **2040s** [21][22] - **Lifecycle Management**: Plans for next-generation products to extend the DUPIXENT franchise, including long-acting formulations [22][24] Charitable Contributions - **Funding Initiatives**: Announced a **$200 million** matching program for charitable contributions in 2026 to support patient access to therapies [15][16] Market Challenges - **Injection Trends**: A **12%** year-over-year decrease in branded injections, with an increase in Avastin usage, indicating competitive pressures [17][18] Conclusion - **Underappreciated Aspects**: The investment in the Regeneron Genetics Center, with **3 million exomes sequenced**, is seen as a competitive advantage for future developments [55][56]

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has shown steady revenue growth, with a 3% increase in fourth-quarter sales compared to the previous year, driven by double-digit growth in three key products [2][3] Sales Performance - Global net sales of DUPIXENT increased by 32%, while LIBTAYO sales rose by 13% on a constant-currency basis [3] - In the U.S., EYLEA HD sales surged by 66%, indicating strong momentum in the domestic market [3] Product Highlights - DUPIXENT is described as a core pillar of Regeneron's business, currently used by over 1.4 million patients worldwide, with further growth anticipated [4] - LIBTAYO has shown progress, particularly in adjuvant CSCC and gaining market share in advanced non-small cell lung cancer, becoming the second most prescribed immunotherapy in the first-line setting in the U.S. [4] Future Outlook - The company has a busy regulatory and development agenda, expecting at least four FDA approvals, including three new molecular entities and the EYLEA HD prefilled syringe [5] - Plans include launching 18 additional Phase III studies over the coming years, with an estimated total enrollment of about 35,000 patients, aimed at supporting the next wave of potential blockbuster products [5]

Core Insights - Regeneron Pharmaceuticals, Inc. reported Q4 2025 results with revenue of $3.9 billion, a 3.0% increase year over year, exceeding consensus expectations by approximately 3% [1] - Adjusted EPS for the quarter reached $11.44, which is 7% above street expectations, indicating strong profitability [1] - The company's performance is driven by four blockbuster medicines and a promising late-stage clinical portfolio, with significant label expansions and new solutions for EYLEA HD [1] Financial Performance - Q4 revenue was $3.9 billion, reflecting a 3.0% year-over-year growth [1] - Adjusted EPS for Q4 was $11.44, exceeding expectations by 7% [1] - BofA Securities projected Q4 collaboration revenues from Sanofi at $1.6 billion, a 32% increase year over year, while Bayer collaboration revenues were estimated at $361 million, down 4% year over year [3] Product Developments - EYLEA HD received label expansions, enhancing its commercial potential [1] - Dupixent has new approvals in Japan and Europe, with over 1.4 million active patients globally, making it the most widely used innovative branded antibody medicine [1] - Libtayo secured additional approvals and remains a leading immunotherapy for non-melanoma skin cancers [1] Analyst Ratings and Projections - BofA Securities maintained a Buy rating with a price target of $860, incorporating the impact of R&D estimates and other disclosures [2] - Evercore ISI raised the price target to $875 from $750, reiterating an Outperform rating, emphasizing Dupixent's growth and Eylea HD's competitive prospects [4] - For 2026, BofA estimated U.S. Eylea franchise revenues at $4.43 billion, higher than previous forecasts and consensus [3]

Core Insights - Regeneron Pharmaceuticals reported strong fourth-quarter performance, with total revenue of $3.9 billion and notable growth in key products like Dupixent, Libtayo, and EYLEA HD, despite challenges in the EYLEA 2 mg segment [5][12] EYLEA HD Performance - EYLEA HD U.S. net product sales reached $506 million in Q4, a 66% increase, and projected to be $1.6 billion for 2025, up 36% [2] - EYLEA 2 mg U.S. net sales declined 15% sequentially to $577 million, indicating competitive pressures [1][8] Libtayo and Dupixent Growth - Libtayo's global net product sales rose 13% to $425 million in Q4, with full-year sales of $1.45 billion, driven by recent FDA approvals [3] - Dupixent's global net sales increased 32% year-over-year to $4.9 billion in Q4, with over 1.4 million patients on therapy [4] Financial Highlights - Regeneron's non-GAAP diluted earnings per share were $11.44, with net income of $1.2 billion, attributed to collaboration revenue and growth in key products [12] - Collaboration revenue from Sanofi was approximately $1.6 billion, a 42% year-over-year increase [13] Regulatory and Pipeline Developments - The company anticipates at least four FDA approvals in the next 12 months, including a prefilled syringe for EYLEA HD [10] - Plans to initiate 18 additional Phase III studies in 2026, targeting a cumulative enrollment of about 35,000 patients [10] Research and Development Focus - R&D budget is projected between $5.9 billion to $6.1 billion, with a gross margin on net product sales expected to be 83% to 84% [15]

Financial Data and Key Metrics Changes - Regeneron reported total revenues of $3.9 billion for Q4 2025, a 3% increase year-over-year, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income reaching $1.2 billion [40] - The company generated $4.1 billion in free cash flow for 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] Business Line Data and Key Metrics Changes - Dupixent achieved global net sales of $4.9 billion in Q4 2025, reflecting a 32% year-over-year growth [36] - EYLEA HD net product sales in the U.S. were $506 million in Q4, up 66% year-over-year, while EYLEA 2 mg sales declined 15% sequentially to $577 million [9][34] - Libtayo reported global net sales of $425 million in Q4, a 13% increase year-over-year, with strong demand across all approved indications [37] Market Data and Key Metrics Changes - Dupixent is now the most widely used innovative branded antibody medicine, with over 1.4 million patients globally [7] - EYLEA HD has become a significant part of Regeneron's anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with a strong market position in advanced non-small cell lung cancer [8][37] Company Strategy and Development Direction - Regeneron aims for at least four FDA approvals in 2026, including three for new molecular entities and the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional Phase III studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron is focused on advancing its pipeline in oncology, immunology, and ophthalmology, leveraging genetics to guide its R&D strategy [68][70] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with U.S. government agencies to reduce drug costs while ensuring patient access to innovative treatments [11] - The company anticipates continued growth in EYLEA HD and Dupixent, with significant opportunities in underpenetrated markets [36][7] - Management highlighted the importance of maintaining a competitive edge through innovative product development and strategic partnerships [70] Other Important Information - Regeneron is committed to helping patients afford their medications, matching a $60 million donation to a fund for retinal disease patients [10] - The company is actively engaging in discussions to address the long-standing imbalance in the distribution of costs for medical innovation [11] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future runway - Management refrained from providing additional comments but acknowledged Sanofi's positive outlook on Dupixent's future [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management emphasized a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management confirmed ongoing development of a potentially improved version of Dupixent, with plans to move it forward in clinical trials [76]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $3.9 billion, reflecting a 3% year-over-year increase, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income of $1.2 billion [40] - Regeneron's share of collaboration profits from Sanofi grew 42% year-over-year, primarily due to Dupixent [41] Business Line Data and Key Metrics Changes - Global net product sales for Dupixent reached $4.9 billion in Q4 2025, a 32% increase year-over-year [7] - Libtayo's global net sales were $425 million in Q4 2025, up 13% year-over-year [37] - EYLEA HD net product sales in the U.S. were $506 million in Q4 2025, representing a 66% increase [9] Market Data and Key Metrics Changes - Dupixent is now approved in eight indications, with over 1.4 million patients on therapy globally, indicating significant market penetration potential [7] - EYLEA HD has become a growing proportion of Regeneron's total anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with strong demand growth across all approved indications [37] Company Strategy and Development Direction - Regeneron anticipates at least four FDA approvals in 2026, including three for new molecular entities and one for the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional phase 3 studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron aims to continue capital deployment for share repurchases, dividends, and complementary business development to drive long-term shareholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with the U.S. government to reduce drug costs while ensuring access to innovative treatments [11] - The company highlighted the importance of its innovative pipeline, with multiple pivotal readouts and regulatory milestones expected in 2026 [30] - Management emphasized the competitive advantages of Dupixent, including its efficacy and safety profile compared to other immunomodulators [59] Other Important Information - Regeneron generated $4.1 billion in free cash flow in 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] - The company initiated a quarterly dividend, providing additional flexibility to return capital to shareholders [45] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future potential - Management refrained from providing additional comments but acknowledged Sanofi's commentary on extending the IP runway [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management confirmed a commitment to a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management discussed the potential of a "souped-up" version of Dupixent that may offer longer-lasting effects and other advantages, with plans to move it forward in clinical development [76]

Core Insights - Regeneron Pharmaceuticals reported strong financial performance in 2025, driven by four blockbuster medicines and a promising late-stage clinical portfolio [2][3] - The company achieved significant label expansions and new approvals for its key products, including EYLEA HD and Dupixent, enhancing their commercial potential [2][4] Financial Highlights - Total revenues for Q4 2025 were $3,884 million, a 3% increase from Q4 2024, while full year revenues reached $14,343 million, up 1% from 2024 [3][14] - GAAP net income for Q4 2025 was $845 million, down 8% from Q4 2024, with a full year GAAP net income of $4,505 million, an increase of 2% [3][14] - Non-GAAP net income for Q4 2025 was $1,249 million, a decrease of 10% from Q4 2024, while full year non-GAAP net income was $4,888 million, down 8% [3][14] Business Highlights - Dupixent global net sales increased by 34% in Q4 2025 to $4.9 billion, with full year sales rising 26% to $17.8 billion [4][14] - EYLEA HD U.S. net sales surged 66% in Q4 2025 to $506 million, with full year sales increasing 36% to $1.6 billion [4][14] - Libtayo received additional approvals and is now the leading immunotherapy for non-melanoma skin cancers [2][4] Pipeline Progress - Regeneron has approximately 45 product candidates in clinical development, with several key updates expected in 2026 [4][10] - Upcoming milestones include FDA decisions for EYLEA HD pre-filled syringe and Dupixent's regulatory submissions for new indications [13][28] Capital Allocation - The company repurchased $671 million of its common stock in Q4 2025 and $3.5 billion for the full year, with $1.5 billion remaining for future repurchases [26] - A cash dividend of $0.94 per share was declared, payable on March 5, 2026 [27] 2026 Financial Guidance - Regeneron projects GAAP R&D expenses between $6.450 billion and $6.680 billion for 2026, with non-GAAP R&D expenses expected to be between $5.900 billion and $6.100 billion [28][29] - The company anticipates a GAAP effective tax rate of 12% to 14% for 2026 [28]

Core Viewpoint - The U.S. stock market is stabilizing after a tech-led sell-off, with investors focusing on futures movements, economic data, and corporate news amid concerns about AI stock valuations and Federal Reserve interest rate policy [1]. Premarket Activity and Futures Movements - U.S. stock futures are trending higher, indicating a potential rebound after Thursday's declines, with Nasdaq 100 futures up 0.17%, S&P 500 futures up 0.31%, and Dow Jones Industrial Average futures up 0.43% [2]. Major Market Indexes - Major U.S. indexes experienced significant losses on Thursday, with the Nasdaq Composite down 2.15%, S&P 500 down 1.56%, and Dow Jones down 0.84%, marking a 2.25-month low for the S&P 500 and a 5-week low for the Dow [4]. Upcoming Market Events and Economic Data - Key economic data releases on November 21 include Johnson/Redbook Weekly Sales, NAHB Housing Market Index, Net Long-term TIC Flows, and preliminary Manufacturing and Services PMI data for various regions [6]. Federal Reserve Interest Rate Expectations - Market sentiment suggests a reduced likelihood of a rate cut in December, with only a 35% chance of a 25-basis-point cut, down from 63.8% a week prior [7]. Major Stock News and Corporate Announcements - Gap shares surged 5.6% due to strong comparable sales, while Intuit gained 3% after reporting strong fiscal results despite light guidance [9]. - Walmart's shares rose over 6% after raising its 2026 net sales forecast, and Regeneron Pharmaceuticals climbed over 4% following FDA approval for its drug [10]. - PACS Group saw a significant jump of over 55% after completing restatements, while Solventum rose over 2% after an acquisition [10][11]. Notable Declines in the Tech Sector - Nvidia shares fell 3.2% despite better-than-expected Q3 results, amid concerns over AI stock valuations, with other major tech stocks also closing lower [12]. - Bath & Body Works plummeted over 24% after missing Q3 sales expectations, and Jacobs Solutions fell over 10% due to disappointing revenue [13].